SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is gaining significant traction amid increasing anticipation for regulatory clarity, with community discussions centered on its potential for expanded institutional adoption and real-world utility. Recent news highlighting reduced exchange supply, potential integrations, and general market momentum are fueling widespread optimism, though some observers remain cautious about sustained independent upward movement.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW, or "crow with knife," is generating significant community buzz, with supporters touting it as a potential life-changing investment akin to early Bitcoin. The narrative highlights its multi-chain presence, deflationary burn mechanism, and organic community strength, aiming to bring substantial volume to the Cronos chain and beyond. Many are actively discussing its potential to rival other popular meme coins.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant upward momentum, driven by strong institutional interest evident in positive ETF flows and aggressive accumulation from new whales. Community discussion is actively centered on speculative geopolitical events and a broadly bullish outlook, creating a notable squeeze on bearish positions. Many anticipate continued upside as Bitcoin solidifies its role as a recognized macro asset amid expanding crypto adoption and a favorable shift in the regulatory environment.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as its new integration with Bridge, a Stripe company, brings live regulated fiat on/off-ramps, positioning it as a crucial infrastructure for institutional digital asset flows. The community is buzzing about Keeta's verified 11 million transactions per second and compliance-first architecture, seeing it as an undervalued opportunity set to redefine global financial plumbing.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is drawing significant attention amid renewed Bitcoin price momentum, intensifying debate over its unique corporate treasury strategy. Community sentiment is sharply divided: bulls anticipate a strong rebound, citing MSTR's undervaluation relative to its Bitcoin holdings and dismissing concerns around an imminent MSCI index review as FUD. Conversely, bears highlight persistent share dilution and the stock's underperformance, predicting further volatility and potential outflows should the index reclassification occur.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is a top trending stock as investors eagerly await its upcoming Q2 earnings report, anticipated to show first-time revenue recognition from its operational Polaris Forge 1 data center and potentially new hyperscaler contracts. The community is highly bullish, viewing this report as a pivotal 'proof of concept' for APLD's position in the surging AI infrastructure market. Discussions around a potential short squeeze are also contributing to the fervent trading interest.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is actively trending following its strategic acquisition of Ask Sage, a generative AI platform for secure environments, coupled with a significant debt reduction initiative. The community is buzzing with anticipation for potential large government contracts in defense and national security, despite ongoing discussions around share dilution. Investors are closely watching if these strategic moves solidify BigBear.ai's position as a crucial AI infrastructure provider in critical sectors.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is surging amid reports of significant geopolitical shifts in Venezuela, where the U.S. is signaling deep involvement in the nation's vast oil industry. As the only major American oil company currently operating there, the community is buzzing with speculation about Chevron's uniquely advantageous position. Investors foresee potential for substantial re-engagement with Venezuela's immense crude reserves, positioning Chevron as a key player in this evolving energy landscape.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is trending as Bitcoin momentum strengthens, fueling investor discussions about its high short interest and potential for a significant squeeze. The community is buzzing with anticipation for developments regarding its strategic pivot into AI and high-performance computing, with many awaiting confirmations of new contracts. This dual focus on crypto mining and emerging AI infrastructure is driving active conversation and debate around its future trajectory.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

ARS Pharmaceuticals ($SPRY) is trending due to significant global market expansion for its needle-free epinephrine nasal spray, Neffy, highlighted by a recent approval in China and ongoing launches in other regions. Investors are actively discussing the potential for a short squeeze, driven by high short interest, diminishing share availability, and rising borrow fees, creating a fervent debate around the stock's market dynamics and its position against competitors in the rapidly evolving allergy treatment sector.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the company...

Kyverna Therapeutics Stock Up 41% in a Month: Here's Why

KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.

Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Buys 133,333 Shares

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) major shareholder Biopartners Opportuni Westlake purchased 133,333 shares of the firm's stock in a transaction dated Thursday, December...

Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Purchases 133,333 Shares

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) major shareholder Biopartners Opportuni Westlake acquired 133,333 shares of Kyverna Therapeutics stock in a transaction that occurred on...

Beth Seidenberg Purchases 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) Director Beth Seidenberg purchased 133,333 shares of the firm's stock in a transaction on Thursday, December 18th. The stock was acquired at...

KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data

Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.

5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026

MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<ul class="summary-bullets"><li>According to the topline data, patients experienced statistical gains in mobility and function.</li><li>All enrolled subjects remained free from ongoing immunotherapies at the last follow-up, and none needed rescue interventions.&nbsp;</li><li>Based on this data, Kyverna plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2026.</li></ul>Kyverna Therapeutics, Inc. (KYTX) shares drew significant investor attention on Monday morning after the company announced promising outcomes from its registrational Phase 2 study of the experimental CAR T-cell therapy mivocabtagene autoleucel (miv-cel) in patients with stiff person syndrome.Stiff person syndrome is a rare and disabling autoimmune condition with no approved treatments.<h2 class="st-heading-2">Positive Trial Outcomes</h2>In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements in both primary and secondary disease measures. The 26 participants enrolled in the study were followed through the main analysis at 16 weeks, with additional observations continuing thereafter.According to the topline data, patients experienced statistical gains in mobility and function. For the primary timed 25-foot walk endpoint, median performance improved 46% compared with baseline, with 81% surpassing a clinically meaningful threshold.&nbsp;Following the trial outcome,&nbsp;<a href="https://stocktwits.com/symbol/KYTX">Kyverna’s stock</a> traded over 11% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;Secondary disability and stiffness indices also improved markedly. Among those who needed walking aids before therapy, two-thirds no longer required assistance by week 16.<h2 class="st-heading-2">Elimination Of Chronic Treatments</h2>All enrolled subjects remained free from ongoing immunotherapies at the last follow-up, and none needed rescue interventions.&nbsp;“Today’s topline data represent a significant breakthrough in the treatment of stiff person syndrome, demonstrating miv-cel’s ability to reverse progressive disability in a debilitating disease that has no approved therapies,” said Naji Gehchan, Chief Medical and Development Officer of Kyverna Therapeutics.&nbsp;Based on this data, Kyverna plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2026.KYTX shares have surged nearly 124% this year.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-goldman-sachs-downgrade-arm-holdings-stock/cLe4GDURE8v">Why Did Goldman Sachs Downgrade Arm Holdings Stock?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Senior Clinical Practice Facilitator Nicole Prescott administering breakthrough treatment to patient Katie Tinkler for lupus at University College London Hospital in London.

KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome?

In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements across both primary and secondary measures of Stiff Person Syndrome.

Equity

In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements across both primary and secondary measures of Stiff Person Syndrome.


Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

KYTX
Kyverna Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KYTX News

KYTXKyverna Therapeutics Inc.